SynthesisCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Diagnostic Risk Prediction Models for Upper Gastrointestinal Cancers: A Systematic Review.
Synthesis in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- GDF15-integrated blood biomarker panel for risk stratification of digestive malignancies: a multicenter retrospective study.Frontiers in pharmacology · 2026Article
- Impact of cancer outcome data source on the diagnostic accuracy of ovarian cancer prediction models: a primary care cohort study.BMJ public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Upper gastrointestinal (UGI) cancers are often detected late. Risk prediction models could facilitate earlier detection by identifying patients at risk for further investigation. We systematically reviewed evidence on UGI diagnostic risk prediction models. A search of MEDLINE, Embase, and CENTRAL was conducted for studies reporting on the development and/or validation of diagnostic risk prediction models for UGI cancers (pancreatic, gastric, esophageal, gallbladder, and/or biliary tract). Studies had to report at least one quantitative measure of model performance to be eligible for inclusion. A total of 82 studies describing 162 UGI risk models were included. Models predicted gallbladder (n = 6), gastric (n = 25), esophageal (n = 34), gastroesophageal (n = 14), and pancreatic (n = 83) cancers. Most models used logistic regression, but machine learning was increasingly used from 2019. In total, 366 unique variables were incorporated across models. Only 33 models were externally validated, with 15 achieving an AUC ≥0.80. This review highlights that several models perform well in predicting UGI cancers on external validation. Future research is needed to compare the best-performing models and assess their clinical utility, acceptability, and cost-effectiveness. Given the significant overlap in at-risk populations and predictors across UGI cancers, there may also be scope to develop UGI "multicancer" models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.